Plain-English translation of NCT04208828 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing whether intravenous immunoglobulin (IVIG)—a medication made from donated antibodies—can help people with autoimmune stomach and nerve problems that haven't gotten better with diet, pills, devices, or other standard treatments. Researchers will give participants the medication in a 12-week course and carefully track how their stomach symptoms change using standardized questionnaires before and after treatment.
Some people develop stomach and nerve problems that are caused by their own immune system attacking their digestive tract, and these problems often don't improve with the usual medications or devices. This medication has shown promise in helping patients who are stuck with severe symptoms, and this study aims to document how well it really works in real-world patients.
You likely qualify if…
You likely don't qualify if…
You will complete questionnaires about your stomach symptoms at the start of the study, then receive at least one 12-week course of the medication given through an IV infusion. After your treatment course is finished, you'll fill out the same symptom questionnaires again so researchers can compare how you're feeling before and after. The study will track your progress and document whether the treatment helps reduce your gastrointestinal symptoms.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States
Sponsor
University of Louisville
Enrollment target
~400 participants
Started
January 2020
Primary completion
January 2028
Age range
12 Years – 90 Years
Last updated on clinicaltrials.gov in August 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Thomas L Abell, MD
University of Louisville
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.